HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells.

AbstractBACKGROUND: Sirolimus-eluting stents (CYPHER stents) demonstrated remarkable efficacy in reducing restenosis rates in patients with coronary artery disease. There is a concern of sub-acute and late stent thrombosis. Tissue factor (TF) is critical in thrombosis. This study investigated the effect of sirolimus on TF expression and activity in cultured human vascular smooth muscle cells (SMCs). METHODS: SMCs were cultured from human saphenous veins and aortas. Quiescent cells were stimulated with sirolimus (0.1 - 20 ng/ml) over 24 hours. Cellular TF expression and activity released into culture medium were measured. The effect of sirolimus on activation of mammalian target of rapamycin (mTOR) was measured by phosphorylation of the substrate p70s6k at T389, and activation of RhoA was measured by pull-down assay. RESULTS: Sirolimus increased TF protein level in cultured human SMCs in a concentration and time-dependent manner (about 2-fold, p < 0.01) reaching maximal effect at 5 ng/ml. The stimulation of TF expression by sirolimus was associated with inhibition of basal activity of mTOR. No effects of sirolimus on RhoA or p38mapk activation that are positive regulators of TF in vascular wall cells were observed. The stimulation of TF expression by sirolimus (20 ng/ml) was prevented by the HMG-CoA reductase inhibitor fluvastatin (1 micromol/L). However, no increase in TF activity released from SMC into culture medium was observed after sirolimus treatment. CONCLUSION: Although sirolimus stimulates TF protein expression in human SMC associated with inhibition of mTOR, it does not enhance TF activity released from the cells, suggesting a relatively safe profile of CYPHER stents. The inhibition of TF expression by fluvastatin favors clinical use of statins in patients undergoing coronary stenting.
AuthorsShengsi Zhu, Hema Viswambharan, Thusitha Gajanayake, Xiu-Fen Ming, Zhihong Yang (Affiliation: Vascular Biology, Department of Medicine, Division of Physiology,University of Fribourg, Rue du Musée 5, CH-1700 Fribourg, Switzerland. zxdyxxy88 at hotmail.com)
JournalBMC cardiovascular disorders (BMC Cardiovasc Disord) Vol. 5 Pg. 22 ( 2005) ISSN: 1471-2261 [Electronic] England
PMID16018822 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Fatty Acids, Monounsaturated
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Sirolimus
  • Thromboplastin
  • fluvastatin
  • Protein Kinases
  • mTOR protein
Topics
  • Aorta
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Fatty Acids, Monounsaturated (pharmacology)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology)
  • Indoles (pharmacology)
  • Muscle, Smooth, Vascular (drug effects, metabolism)
  • Myocytes, Smooth Muscle (drug effects, metabolism)
  • Protein Kinases (metabolism)
  • Saphenous Vein
  • Sirolimus (pharmacology)
  • Thromboplastin (biosynthesis, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD